

# Fecal microbiota transplantation in ulcerative colitis, a retrospective microbiome analysis



Marcel A. de Leeuw & Manuel X. Duval, GeneCreek

## Contents

<b>Introduction</b>	<b>1</b>
<b>Materials &amp; Methods</b>	<b>1</b>
Data analysis . . . . .	2
<b>Results</b>	<b>2</b>
Dysbiosis in IMIDs . . . . .	2
Responder and non-responder patients . .	2
Responder and non-responder donors . . .	3
Responder and non-responder species . . .	3
<b>Discussion</b>	<b>4</b>
<b>Conclusions</b>	<b>5</b>
<b>Acknowledgements</b>	<b>5</b>
<b>Bibliography</b>	<b>5</b>

## List of Figures

1	Species diversity in IMIDs . . . . .	2
2	Strict anaerobes proportion in IMIDs . . . . .	2
3	Patient microbiome phylogenetic diversity (left) and oxygen tolerance (right) . . . . .	3
4	Donor microbiome features, data set ERP013257 . .	3
5	Donor microbiome assessment, data set ERP013257	3
6	Ecological network of responder and non-responder associated species . . . . .	4
7	Cladogram of responder and non-responder associated species . . . . .	4

## List of Tables

1	Clinical trial data sets used in the study . . . . .	1
2	Profiling data sets used in the study . . . . .	2

# Fecal microbiota transplantation in ulcerative colitis, a retrospective microbiome analysis

Marcel A. de Leeuw & Manuel X. Duval, GeneCreek

**Background.** Inflammatory bowel disease (IBD) is a set of conditions characterized by non-infectious chronic inflammation of the gastrointestinal tract. These primarily include Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis. Fecal microbiota transplantation (FMT) has proven to be an effective treatment for some patients with active UC. However, factors contributing to the individual response to FMT therapy remain to be uncovered. There is currently no procedure allowing to predict the patients' response and to select the most adequate donor(s).

**Methods.** The first available UC FMT microbiome data sets were reanalyzed, with focus on species level changes in the microbiota, using state-of-the-art and in part proprietary 16S analysis routines.

**Results.** We found the microbiomes of UC and CD patients to have paucity of obligate anaerobes, which could be a consequence of oxidative stress. Microbiomes of UC FMT responders and responder donors have higher phylogenetic diversity and a higher proportion of aerobes and facultative anaerobes as compared to non-responders and non-responder donors. We found *Proteobacteria* to account for the major part of species found in increased relative abundance in responders. Sphingolipid producers were found among these species.

**Implications.** Our findings contribute to the establishment of selection criteria for UC FMT donor samples and composition guidelines for future synthetic microbial communities. Instead of replenishing missing obligate anaerobes, our results suggest that oxidative stress resistant *Proteobacteria* are important for successful UC FMT therapy.

## Introduction

The incidence and prevalence of inflammatory bowel disease (IBD) is increasing worldwide. It can affect people of all ages, including children and geriatric populations, and can impact all aspects of life. The Global number of cases of IBD reached 6.8 million in 2017, with the highest age-standardized prevalence rates in the U.S.A. and the U.K. [GBD 2017 IBD Collaborators 2020]. IBD is characterized by non-infectious chronic inflammation of the gastrointestinal tract, and primarily includes Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis. Whereas CD can affect any part of the gastroesophageal tract from the mouth to the anus, UC is confined to the large bowel. Diagnosis of IBD relies on a combination of medical history, physical examination, laboratory testing, and endoscopy with biopsy [Sairenji et al. 2017]. Treatment goals for IBD are to minimize symptoms, improve quality of life, and minimize progression and complications of the disease. Most treatments for UC target the immune system through mediators of the inflammatory cascade, but a substantial proportion of UC patients continue to have inadequate disease control.

Microbes may increase susceptibility to IBD, e.g. by producing bioactive metabolites that affect immune activity and epithelial function. Fecal microbiota transplantation (FMT) is a therapeutic procedure aimed at replacing pro-inflammatory intestinal microbiota with physiological/commensal species by the administration of filtered fecal material from a healthy donor into the intestinal tract of a patient. A number of studies, including randomized controlled trials [Moayyedi et al. 2015, Paramsothy et al. 2017; 2019, Costello et al. 2019], sug-

gest that FMT is effective in the treatment of patients with active UC, for approximately one out of three patients. For FMT to be successful in complex immune diseases like UC, it is assumed that therapeutic microbes must colonize the recipient's intestinal tract and persist in sufficient quantity and for a long enough period of time to result in a clinical benefit. It is as yet unclear which donor- and recipient related factors contribute to a successful clinical response.

We combined a series of relevant microbiome studies, available in the form of raw 16S data, in order to increase statistical power and to address elementary microbiome composition pertaining to the clinical endpoint.

**Table 1:** Clinical trial data sets used in the study. N: number of patients, n: number of samples, 16S: variable regions covered.

BioProject	SRA	N	n	type	16S
PRJEB26474	ERP108465	81	158	biopsy	V1-V2
PRJEB26472	ERP108463	81	309	stool	V1-V2
PRJNA515212	SRP180003	7	42	stool	V3-V4
PRJEB33851	ERP116682	28	98	stool	V4
PRJEB11841	ERP013257	27	172	stool	V4
PRJNA475599	SRP198502	12	235	stool	V4
PRJNA380944	SRP102742	21	109	stool	V4
PRJNA438164	SRP135559	7	21	stool	V4
PRJNA388210	SRP108284	20	78	stool	V4
total		203	1,222		

## Materials & Methods

The materials summarized in Table 1 have been made available as part of clinical trials. For the purpose of profiling ulcerative colitis and Crohn's disease micro-

biomes, we also used the published datasets in Table 2.

**Table 2:** Profiling data sets used in the study. N: number of patients, n: number of samples, 16S: variable regions covered.

BioProject	SRA	N	n	type	16S
PRJNA450340	SRP183770	79	201	stool	V4
PRJNA422193	SRP128892	67	423	stool	V4
PRJNA398089	SRP115494	81	176	biopsy	V4
total		227	800		

## Data analysis

Amplicon Sequence Variants (ASVs) were generated with the R Bioconductor package `dada2`, version 1.12.1 with recommended parameters [McMurdie, Paul J et al. 2016], involving quality trimming, discarding of sequences with N's, assembly of forward and reverse sequences and contamination and chimera removal. The top 50,000 ASVs were retained for further analysis, involving multiple alignment with `mafft`, version 6.603b [Katoh et al. 2009] and approximately-maximum-likelihood phylogenetic tree generation with `FastTreeMP`, version 2.1.11 [Price, Morgan N et al. 2010], both with default settings.

Taxonomic classification of ASVs was performed by `cur|sor`, an in-house Python and R program using random forest based supervised learning on the Ribosomal Database Project (RDP) release 11.5. Resulting classifications are available from the github repository <https://github.com/GeneCreek/UC-manuscript> in the form of R data objects.

Detection of responder and non-responder associated taxa was performed with negative binomial differential analysis implemented by the R Bioconductor package `DESeq2` [Love et al. 2014], using Wald significance tests and local fitting, requiring  $p_{Adj} < 0.001$ .

Responder status classification was performed using the R package `caret` using the partial least squares (PLS) method with 10 fold cross-validation and sampling of subjects to account for multiple microbiomes per subject.

Ecological networks were computed using inverse covariance with SPIEC-EASI [Kurtz et al. 2015] as incorporated in the R Bioconductor package `SpiecEasi`, version 1.0.7, using default parameters. Community structure was detected using `cluster_edge_betweenness` as provided by the R package `igraph`.


The cladogram was generated by in-house R scripts using the R package `ggtree`, version 2.0.1. [Yu 2020].

## Results


### Dysbiosis in IMIDs

We initiated our study by describing the distribution of two fecal microbiome co-variates, (the species diversity with the Shannon diversity index and the strict anaerobes proportion) in UC samples within the context of other immune mediated inflammatory diseases (IMIDs),

[Forbes et al. 2018], Fig. 1 respectively Fig. 2.



**Figure 1:** Species diversity in IMIDs. Numbers reflect Wilcoxon p-values. HC: healthy controls, MS: multiple sclerosis, UC: ulcerative colitis, RA: rheumatoid arthritis, CD: Crohn's disease



**Figure 2:** Strict anaerobes proportion in IMIDs. Numbers reflect Wilcoxon p-values. HC: healthy controls, MS: multiple sclerosis, UC: ulcerative colitis, RA: rheumatoid arthritis, CD: Crohn's disease


The ranking of the IMID's diseases is the same according to these two metrics, with notably rheumatoid arthritis positioned between ulcerative colitis and Crohn's disease. Several publications have reported dysbiosis in UC can be reduced through FMT. This principle is illustrated using data set SRP108284 and Chao species richness in supplemental Fig. S1. The improvement reaches statistical significance in the samples collected in the second week after a single FMT, but washes out subsequently in the fourth week.

Just like species diversity, the strict anaerobe proportion can be modified through FMT, Fig. S2. The two donors used in study SRP198502 were selected based on fecal butyrate concentration [Chu et al. 2020] and had a high proportion of strict anaerobes.


### Responder and non-responder patients

Combining the UC patients in data sets ERP013257, SRP135559, ERP116682 and SRP102742 totaling 49 responders and non-responders to FMT, we tested several microbiome covariates in relation to the responder status, two of which reached significance: the phylogenetic diversity at screening and the oxygen tolerance

post FMT, Fig. 3.



**Figure 3:** Patient microbiome phylogenetic diversity (left) and oxygen tolerance (right). Combined data set. Numbers reflect Wilcoxon p-values. NR: nonresponders, RE: responders.




**Figure 4:** Donor microbiome features, data set ERP013257. Numbers reflect Wilcoxon p-values. NR: nonresponders, PR: partial responders, RE: responders.

### Responder and non-responder donors

Data set ERP013257 comprises 51 samples from 12 donors which are associated with either non-response, partial response or response to UC treatment with FMT [Kump et al. 2017]. We again tested several microbiome covariates, this time in relation to the responder donor status. The same covariates as for the patients, i.e. phylogenetic diversity and oxygen tolerance reached significance, Fig. 4.

Plotting the relation between phylogenetic diversity and oxygen tolerance for donor samples, we found these are related and separate responder and non-responder associated donors, Fig. 5. Phylogenetic diversity shows important variance around the donor means.




**Figure 5:** Donor microbiome assessment, data set ERP013257. Lines connect samples from the same donor. NR: nonresponders, PR: partial responders, RE: responders.


### Responder and non-responder species

Through DESeq analysis, we obtained 135 species with differential relative abundance ( $p_{Adj} < 0.001$ ) comparing the post FMT microbiomes of non-responders and responders. Predictive modeling applying the partial least squares (PLS) classifier with 10 fold cross validation and 20 repeats using these species as input features returned a model predicting responders and non-responders with a median area under the curve of 0.751.

The same DESeq detected species were used as input for ecological network generation, Fig. 6. Clustering analysis of this network revealed the largest community ( $n=33$ ) is exclusively responder associated, Table S1. These species are in majority *Proteobacteria* - gram-negative (30/33) aerobes or facultative aerobes (32/33) among which we found four *Sphingomonadaceae* species, *Sphingopyxis ginsengisoli*, *Sphingobium subterraneum*, *Sphingomonas kwangyangensis* and *Sphingomonas melonis*. The remaining 22 responder associated species are a mixture of gram positive and gram negative species in majority anaerobes (15/22), Table S2. Figure 7 provides a cladogram of responder and non-responder associated species.



**Figure 6:** Ecological network of responder and non-responder associated species. Only species with interactions are displayed. Responder associations are based on positive log fold change in relative abundance. Co-exclusion is indicated in red.



**Figure 7:** Cladogram of responder and non-responder associated species.

We tested available donor samples (n=134) for the detectable presence of identified responder associated species. Only a minority (5/33) of *Proteobacteria* were found in donor samples, whereas on the opposite, a majority (17/22) of anaerobe species could be traced back to donor samples.

## Discussion

Oxidative stress has been proposed as a mechanism underlying the pathophysiology of CD [Alzoughaibi 2013] and has long been known as a pathogenic factor of UC [Wang et al. 2016]. If radical oxygen species (ROS) are released in the lumen, we may expect modulation of

the microbiome composition. Indeed, we observe a decreased proportion of strict anaerobes in the microbiome composition of UC and CD samples, accompanied by loss of species diversity. The loss of obligate anaerobes in IBD has been reported previously [Lloyd-Price et al. 2019]. Thus we postulate oxidative stress in IMIDs drives the decrease in obligate anaerobes, which results in the loss of microbial diversity and loss of function such as butyrate production.

However, it does not seem from our results that engrafting of obligate anaerobes is important for remission - their proportion increases in responders, but does not reach significance (results not shown). Rather, what seems important is the transfer of facultative anaerobes, which we found increased in both responder-associated donor stool and in responder patient stool as compared to non-responders. In particular we detected *Proteobacteria* in responders, with an important level of ecological network interaction, suggesting formation of biofilms. These bacteria could emerge from either trace amounts in donor samples or environmental sources including the FMT procedure itself. Intriguingly, it has been shown that *Proteobacteria* are responsible for the major part of functional gut microbiome variation between individuals, including LPS biosynthesis [Bradley and Pollard 2017]. *Proteobacteria* could also provide for in situ glutathione (GSH) production in the gut, possibly mitigating the oxidative stress in the intestinal lining.

We found differentially expressed *Bacteroides*, *Lactobacillus* and *Streptococcus* species to be associated with non-responder status, with a few exceptions, e.g. *Lactobacillus mucosae*. For the *Bacteroides* species, none of the species identified are predominant in the gut. *Streptococci* have been associated with increased disease activity in IBD [Heidarjan et al. 2017].

It has been reported *Bacteroides* derived sphingolipids are depleted in IBD. These lipids are critical for maintaining intestinal homeostasis and symbiosis [Brown et al. 2019]. Our results suggest *Spingomonaceae* which we found associated with responder status, could provide such sphingolipids in the gut as well.

The following additional four microbiome-related quantities have been found to be associated with the FMT response status:

- Increased presence of *Pseudomonas* species in IBD has been described [Wagner et al. 2008]. All three *Pseudomonas* species we identified, *P. aeruginosa*, *P. fluorescence* and *P. putida* were associated with responder status. This is surprising for the opportunistic pathogen *P. aeruginosa*, which solicits inflammatory response in immunocompromised patients through its highly variable LPS [Pier 2007].

- Also noteworthy is the presence of four methane metabolizers among the species associated with responder status, *Methylobacterium adhaesivum* *Methylobacterium populi* *Methylomonas methanica* and

*Methyloversatilis universalis*. This is paradoxical, since lower methane production is thought to be a hallmark of IBD, with unknown mechanism [Monasta et al. 2017].

- We found four non-pathogenic *Acinetobacter* species to be associated with response. Association of *Acinetobacter* with inflamed tissue in IBD has been described [Leung et al. 2014]. Our results indicate *Acinetobacter* presence may actually be beneficial in the context of FMT.

- Lastly, the pre-existing phylogenetic diversity in receivers is predictive for remission after FMT. This constitutes a potential criterion for the FMT therapeutic decision.

## Conclusions

In conclusion, we found the microbiomes of UC and CD patients to have paucity of obligate anaerobes, which could be related to oxidative stress. Microbiomes of UC FMT responders and responder donors have higher phylogenetic diversity and a higher proportion of aerobes and facultative anaerobes as compared to non-responders and non-responder donors. We found Proteobacteria to account for the major part of species detected in increased relative abundance in responders. Sphingolipid producers were found among these species. Thus, instead of replenishing missing obligate anaerobes, our results suggest supplementing with more oxidative stress resistant Proteobacteria, which can be seen as a paradigm shift. These findings should contribute to the establishment of selection criteria for UC FMT donor samples and composition guidelines for future synthetic microbial communities.

## Acknowledgements

The authors acknowledge the contributions to the Short Read Archive made by the respective institutions and acknowledge scientific journals for enforcing this practice.

## Bibliography

Mohammed A Alzoughaibi. Concepts of oxidative stress and antioxidant defense in Crohn's disease. *World journal of gastroenterology : WJG*, 19(39):6540–6547, October 2013. doi: 10.3748/wjg.v19.i39.6540.

Patrick H Bradley and Katherine S Pollard. Proteobacteria explain significant functional variability in the human gut microbiome. *Microbiome*, 5(1):36–23, March 2017. doi: 10.1186/s40168-017-0244-z.

Eric M Brown, Xiaobo Ke, Daniel Hitchcock, Sarah Jeanfavre, Julian Avila-Pacheco, Toru Nakata, Timothy D Arthur, Nadine Fornelos, Courtney Heim, Eric A Franzosa, Nicki Watson, Curtis Huttenhower, Henry J Haiser, Glen Dillow, Daniel B Graham, B Brett Finlay, Aleksandar D Kostic, Jeffrey A Porter, Hera Vlamakis, Clary B Clish, and Ramnik J Xavier. Bacteroides-Derived Sphingolipids Are Critical for Maintaining Intestinal Homeostasis and Symbiosis. *Cell host & mi-*

*crobe*, 25(5):668–680.e7, May 2019. doi: 10.1016/j.chom.2019.04.002.

Nathaniel D Chu, Jessica W Crothers, Le T T Nguyen, Sean M Kearney, Mark B Smith, Zain Kassam, Cheryl Collins, Ramnik Xavier, Peter L Moses, and Eric J Alm. Dynamic colonization of microbes and their functions after fecal microbiota transplantation for inflammatory bowel disease. *bioRxiv*, 2:17004–36, January 2020. doi: 10.1101/649384.

Samuel P Costello, Patrick A Hughes, Oliver Waters, Robert V Bryant, Andrew D Vincent, Paul Blatchford, Rosa Katsikeros, Jesica Makanyanga, Melissa A Campaniello, Chris Mavrangelos, Carly P Rosewarne, Chelsea Bickley, Cian Peters, Mark N Schoeman, Michael A Conlon, Ian C Roberts-Thomson, and Jane M Andrews. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. *JAMA*, 321(2):156–164, January 2019. doi: 10.1001/jama.2018.20046.

Jessica D Forbes, Chih-Yu Chen, Natalie C Knox, Ruth-Ann Marrie, Hani El-Gabalawy, Teresa de Kievit, Michelle Alfa, Charles N Bernstein, and Gary Van Domselaar. A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist? *Microbiome*, 6(1):221–15, December 2018. doi: 10.1186/s40168-018-0603-4.

GBD 2017 IBD Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Gastroenterology & Hepatology*, 5(1):17–30, January 2020. doi: 10.1016/S2468-1253(19)30333-4.

Farnaz Heidarian, Zahra Noormohammadi, Hamid Asadzadeh Aghdaei, and Masoud Alebouyeh. Relative Abundance of *Streptococcus* spp. and its Association with Disease Activity in Inflammatory Bowel Disease Patients Compared with Controls. *Archives of Clinical Infectious Diseases*, pages 1–7, April 2017. doi: 10.5812/archcid.57291.

Kazutaka Katoh, George Asimenos, and Hiroyuki Toh. Multiple alignment of DNA sequences with MAFFT. *Methods in molecular biology (Clifton, N.J.)*, 537(Suppl 5):39–64, 2009. doi: 10.1007/978-1-59745-251-9\_3.

P Kump, P Wurm, H P Gröchenig, H Wenzl, W Petritsch, B Halwachs, M Wagner, V Stadlbauer, A Eherer, K M Hoffmann, A Deutschmann, G Reicht, L Reiter, P Slawitsch, G Gorkiewicz, and C Högenauer. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. *Alimentary Pharmacology & Therapeutics*, 47(1):67–77, October 2017. doi: 10.1111/apt.14387.

- Zachary D Kurtz, Christian L Müller, Emily R Miraldi, Dan R Littman, Martin J Blaser, and Richard A Bonneau. Sparse and compositionally robust inference of microbial ecological networks. *PLoS Computational Biology*, 11(5):e1004226, May 2015. doi: 10.1371/journal.pcbi.1004226.
- J M Leung, M Davenport, M J Wolff, K E Wiens, W M Abidi, M A Poles, I Cho, T Ullman, L Mayer, and P Loke. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. *Mucosal immunology*, 7(1):124–133, January 2014. doi: 10.1038/mi.2013.31.
- Jason Lloyd-Price, Cesar Arze, Ashwin N Ananthkrishnan, Melanie Schirmer, Julian Avila-Pacheco, Tiffany W Poon, Elizabeth Andrews, Nadim J Ajami, Kevin S Bonham, Colin J Brislawn, David Casero, Holly Courtney, Antonio González, Thomas G Graeber, A Brantley Hall, Kathleen Lake, Carol J Landers, Himel Mallick, Damian R Plichta, Mahadev Prasad, Ghohrali Rahnavard, Jenny Sauk, Dmitry Shungin, Yoshiki Vázquez-Baeza, Richard A White, IBDMDB Investigators, Jonathan Braun, Lee A Denson, Janet K Jansson, Rob Knight, Subra Kugathasan, Dermot P B McGovern, Joseph F Petrosino, Thaddeus S Stappenbeck, Harland S Winter, Clary B Clish, Eric A Franzosa, Hera Vlamakis, Ramnik J Xavier, and Curtis Huttenhower. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature*, 569(7758):655–662, May 2019. doi: 10.1038/s41586-019-1237-9.
- Michael I Love, Wolfgang Huber, and Simon Anders. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology*, 15(12):550, 2014. doi: 10.1186/s13059-014-0550-8.
- McMurdie, Paul J, Rosen, Michael J, Han, Andrew W, Johnson, Amy Jo A, Holmes, Susan P, and Callahan, Benjamin J. DADA2: High-resolution sample inference from Illumina amplicon data. *Nature Methods*, pages 1–7, May 2016. doi: 10.1038/nmeth.3869.
- Paul Moayyedi, Michael G Surette, Peter T Kim, Josie Libertucci, Melanie Wolfe, Catherine Onischi, David Armstrong, John K Marshall, Zain Kassam, Walter Reinisch, and Christine H Lee. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology*, 149(1):102–109.e6, July 2015. doi: 10.1053/j.gastro.2015.04.001.
- Lorenzo Monasta, Chiara Pierobon, Andrea Princivalle, Stefano Martelossi, Annalisa Marcuzzi, Francesco Pasini, and Luigi Perbellini. Inflammatory bowel disease and patterns of volatile organic compounds in the exhaled breath of children: A case-control study using Ion Molecule Reaction-Mass Spectrometry. *PLoS ONE*, 12(8), 2017. doi: 10.1371/journal.pone.0184118.
- Sudarshan Paramsothy, Michael A Kamm, Nadeem O Kaakoush, Alissa J Walsh, Johan van den Bogaerde, Douglas Samuel, Rupert W L Leong, Susan Connor, Watson Ng, Ramesh Paramsothy, Wei Xuan, Enmoore Lin, Hazel M Mitchell, and Thomas J Borody. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet (London, England)*, 389(10075):1218–1228, March 2017. doi: 10.1016/S0140-6736(17)30182-4.
- Sudarshan Paramsothy, Shaun Nielsen, Michael A Kamm, Nandan P Deshpande, Jeremiah J Faith, Jose C Clemente, Ramesh Paramsothy, Alissa J Walsh, Johan van den Bogaerde, Douglas Samuel, Rupert W L Leong, Susan Connor, Watson Ng, Enmoore Lin, Thomas J Borody, Marc R Wilkins, Jean-Frederic Colombel, Hazel M Mitchell, and Nadeem O Kaakoush. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. *Gastroenterology*, 156(5):1440–1454.e2, April 2019. doi: 10.1053/j.gastro.2018.12.001.
- Gerald B Pier. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. *International Journal of Medical Microbiology*, 297(5):277–295, September 2007. doi: 10.1016/j.ijmm.2007.03.012.
- Price, Morgan N, Dehal, Paramvir S, and Arkin, Adam P. FastTree 2—approximately maximum-likelihood trees for large alignments. *PLoS ONE*, 5(3):e9490, March 2010. doi: 10.1371/journal.pone.0009490.
- Tomoko Sairenji, Kimberly L Collins, and David V Evans. An Update on Inflammatory Bowel Disease. *Primary care*, 44(4):673–692, December 2017. doi: 10.1016/j.pop.2017.07.010.
- Josef Wagner, Kirsty Short, Anthony G Catto-Smith, Don J S Cameron, Ruth F Bishop, and Carl D Kirkwood. Identification and characterisation of Pseudomonas 16S ribosomal DNA from ileal biopsies of children with Crohn’s disease. *PLoS ONE*, 3(10):e3578, 2008. doi: 10.1371/journal.pone.0003578.
- Zhiqi Wang, Sai Li, Yu Cao, Xuefei Tian, Rong Zeng, Duan-Fang Liao, and Deliang Cao. Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer. *Oxidative medicine and cellular longevity*, 2016(3):9875298–15, 2016. doi: 10.1155/2016/9875298.
- Guangchuang Yu. Using ggtree to Visualize Data on Tree-Like Structures. *Current Protocols in Bioinformatics*, 69(1):96, March 2020. doi: 10.1002/cpbi.96.